While promising anti-tumor effects have been reported in specific contexts—such as HER2-positive breast cancer, colorectal cancer, and metabolically distinct lung cancer subtypes—clinical efficacy remains variable. This evidence concerns the gene ERBB2 and breast carcinoma.